NASDAQ$KALV
KalVista Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
KalVista reported second fiscal quarter results and provided an operational update.
KalVista Pharmaceuticals reported no revenue for the quarter ended October 31, 2023. The company's net loss was $27.7 million, or $(0.80) per share. Cash, cash equivalents and marketable securities were $103.2 million as of October 31, 2023. The KONFIDENT trial achieved the targeted number of attacks to complete the trial.
- Achieved the targeted number of on-treatment attacks required to complete the phase 3 KONFIDENT trial, with topline data expected in early 2024 and NDA submission in the first half of 2024.
- Received Orphan Drug Status (ODS) approval from Switzerland for sebetralstat.
- Presented real-world patient data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.
- Conducted fireside chats at the Cantor Global Healthcare Conference, Stifel 2023 Healthcare Conference, and Jefferies London Healthcare Conference.
Headline financials
Revenue & EPS history
KalVista · Revenue · Quarterly
$0
Forward guidance
KalVista anticipates providing data from the phase 3 KONFIDENT clinical trial in early 2024 and expects to file for approval in the European Union and Japan later in 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.3%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.7%
Avg return
30 days after
49%
21 / 43 earnings
Positive
+20.3%
Q4 2018
Best reaction
-26.3%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +1.1% | +26.3% | +56.4% | |
| Q1 2026 | -3.8% | -12.3% | -25.3% | |
| Q4 2025 | -3.1% | -5.1% | -22.4% | |
| Q3 2025 | +2.0% | -2.6% | +5.1% | |
| Q2 2025 | -4.2% | -0.2% | -4.5% | |
| Q1 2025 | -4.5% | -13.2% | -12.1% | |
| Q4 2024 | +3.7% | +21.3% | +2.6% | |
| Q3 2024 | -13.0% | -16.9% | -16.9% | |
| Q2 2024 | -9.0% | +8.8% | +26.8% | |
| Q1 2024 | -4.0% | -4.2% | -12.2% | |
| Q4 2023 | +17.0% | +7.6% | +23.5% | |
| Q3 2023 | -10.4% | -1.3% | +2.7% | |
| Q2 2023 | +9.8% | +7.3% | +27.8% | |
| Q1 2023 | +1.4% | -2.5% | -68.4% | |
| Q4 2022 | +10.6% | +18.0% | +37.5% | |
| Q3 2022 | -9.3% | -14.6% | -16.4% | |
| Q2 2022 | -0.4% | -2.9% | -4.2% | |
| Q1 2022 | -0.6% | -6.0% | -14.4% | |
| Q4 2021 | -3.0% | -2.9% | -14.0% | |
| Q3 2021 | +3.4% | +8.9% | -16.8% | |
| Q2 2021 | +5.2% | +5.1% | -7.0% | |
| Q1 2021 | +2.0% | +1.3% | +9.8% | |
| Q4 2020 | +7.2% | +4.2% | -18.8% | |
| Q3 2020 | -26.3% | -41.2% | -20.9% | |
| Q2 2020 | -1.8% | -5.7% | +18.9% | |
| Q1 2020 | +8.7% | +1.0% | -29.4% | |
| Q4 2019 | -0.5% | +1.4% | -6.7% | |
| Q3 2019 | +10.4% | +7.6% | -0.2% | |
| Q2 2019 | -14.0% | -21.2% | -15.5% | |
| Q1 2019 | +9.6% | +4.6% | +20.6% | |
| Q4 2018 | +20.3% | +29.8% | +94.0% | |
| Q3 2018 | +4.7% | +11.7% | +0.8% | |
| Q2 2018 | -4.8% | -12.3% | +0.2% | |
| Q1 2018 | -21.5% | -23.6% | +9.8% | |
| Q4 2017 | -0.8% | -2.7% | -11.6% | |
| Q3 2017 | +1.9% | -1.0% | -12.2% | |
| Q2 2017 | -1.9% | -2.9% | -1.6% | |
| Q1 2017 | +0.4% | +13.1% | -13.3% | |
| Q4 2016 | -3.2% | — | — | |
| Q3 2016 | +7.1% | — | — | |
| Q2 2016 | -3.2% | — | — | |
| Q1 2016 | +1.3% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro